Recent reading
Evidence brief · 2026-09-11
Tesamorelin vs Ipamorelin: What the Evidence Actually Compares
A plain-language look at authorization, study populations, outcomes, and safety limits—without turning two different evidence bases into a treatment scorecard.
Read the brief →Evidence brief · 2026-09-11
BPC-157 vs TB-500: What the Evidence Actually Shows
A plain-language evidence brief separating animal findings, small human studies, the TB-500 fragment, and full-length thymosin beta-4—without treating a comparison as a treatment ranking.
Read the brief →Evidence brief · 2026-09-11
CJC-1295 vs Ipamorelin: What the Human Evidence Actually Shows
A plain-language evidence brief separating CJC-1295 DAC hormone studies from no-DAC product labels, ipamorelin pharmacology, and what current U.S. FDA records do—and do not—establish.
Read the brief →Evidence brief · 2026-09-24
Glow Protocol: Ingredients, Evidence & Safety
A plain-language review of the marketed GHK-Cu, BPC-157, and TB-500 Glow blend, separating ingredient research from blend evidence, route differences, safety, and U.S. regulatory status.
Read the brief →Evidence brief · 2026-09-27
Considering Peptides? 10 Peptides to Know and What the Benefits Evidence Shows
An approachable guide to 10 individual peptides, why people are interested in them, and what human studies actually show about their proposed benefits.
Read the brief →